Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0U2DO
|
||||
| Former ID |
DIB016180
|
||||
| Drug Name |
FP-1039
|
||||
| Synonyms |
FPT-039; HGS-1036; Modified growth factor receptor (cancer), FivePrime Therapeutics; FGFR-1c antagonist (protein fusion/iv,cancer), FivePrime Therapeutics; FGFR-1c antagonist (protein fusion/iv, cancer), FivePrime Therapeutics/ Human Genome Sciences
|
||||
| Indication | Endometrial cancer [ICD9: 182; ICD10:C54.1] | Phase 2 | [523259] | ||
| Company |
FivePrime Therapeutics Inc
|
||||
| Target and Pathway | |||||
| Target(s) | Basic fibroblast growth factor receptor 1 | Target Info | Antagonist | [544282] | |
| KEGG Pathway | MAPK signaling pathway | ||||
| Ras signaling pathway | |||||
| Rap1 signaling pathway | |||||
| PI3K-Akt signaling pathway | |||||
| Adherens junction | |||||
| Signaling pathways regulating pluripotency of stem cells | |||||
| Regulation of actin cytoskeleton | |||||
| Pathways in cancer | |||||
| Proteoglycans in cancer | |||||
| Prostate cancer | |||||
| Melanoma | |||||
| Central carbon metabolism in cancer | |||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| PANTHER Pathway | Angiogenesis | ||||
| FGF signaling pathway | |||||
| Pathway Interaction Database | Glypican 1 network | ||||
| Syndecan-4-mediated signaling events | |||||
| N-cadherin signaling events | |||||
| FGF signaling pathway | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.